Purchase this article with an account.
DB Roth, M Spirn, DL Yarian, SN Green, SR Leff, ES Friedman, BJ Keyser, MH Wheatley; Intravitreal Triamcinolone Injection for the Treatment of Occult Choroidal Neovascularization associated with Age-related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2500.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To study the effect of intravitreal injection of triamcinolone as treatment for occult subfoveal choroidal neovascularization associated with age-related macular degeneration (ARMD). Method: Eight eyes of seven patients with occult choroidal neovascularization associated with ARMD were treated. The visual acuity before treatment ranged from 20/80 to 4/200. All patients were evaluated with pre-treatment fluorecein angiography (FA). The size of choroidal neovascularization on FA ranged from 2.5 mm to 7.0 mm in greatest linear diameter. Three eyes had received prior laser photocoagulation before triamcinolone injection. Treatment consisted of a single intravitreal injection of 4 mg of triamcinolone through the pars plana under sterile conditions. A paracentesis was performed if the intraocular pressure was above 40 mm Hg after injection. Several patients required repeat trimacinolone injections over follow-up for persistent or recurrent leakage on fluorescein angiography. Results: None of the patients experienced visual loss over the initial follow-up period. Three eyes experienced an improvement of 3 or more lines of Snellen visual acuity. A stabilization or reduction of subretinal fluid was seen in all patients. Conclusion: Intravitreal injection of triamcinolone appears to be an effective treatment modality for occult choroidal neovascularization in patients with ARMD. Repeat injections may be necessary to address persistent or recurrent choroidal neovascular leakage. The lasting effect of this treatment needs further study with longer follow-up.
This PDF is available to Subscribers Only